Why ABIVAX Société Anonyme’s (ABVX) Stock Is Up 6.12%
As of Thursday, July 02, ABIVAX Société Anonyme’s ABVX share price has surged by 6.12%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Commentary & Analysis
Why ABIVAX Société Anonyme’s (ABVX) Stock Is Up 35.67%
As of Tuesday, June 30, ABIVAX Société Anonyme’s ABVX share price has surged by 35.67%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why ABIVAX Société Anonyme’s (ABVX) Stock Is Up 38.07%
As of Tuesday, June 30, ABIVAX Société Anonyme’s ABVX share price has surged by 38.07%, which has investors questioning if this is right time to sell.Tudor Pop
Why ABIVAX Société Anonyme’s (ABVX) Stock Is Down 15.18%
As of Wednesday, June 24, ABIVAX Société Anonyme’s ABVX share price has dipped by 15.18%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why ABIVAX Société Anonyme’s (ABVX) Stock Is Up 5.44%
As of Wednesday, June 17, ABIVAX Société Anonyme’s ABVX share price has surged by 5.44%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ABVX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $10,481.8 | $288.9 | 78% |
|
| Shares Out (Mil) | 91.0 | 54.0 | 60% |
|
| Institutional Ownership | 99.4% | 93.1% | 88% |
|
| Float (Mil) | 82.8 | 41.4 | 57% |
|
| Beta | -0.23 | 0.94 | 3% |
|
| Avg Daily Volume (000s) | 976 | 480 | 71% |
|
| Price Change (52-week) |
35.5% | 59.9% | 74% |
|
| Growth | ABVX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (53.8%) | (10.1%) | 6% |
|
| EPS (5yr) | (12.1%) | 15.9% | 20 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 31.2% | (15.6%) | 87% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 6 | 6 | |
| Current EPS | ($0.905) | ($3.584) | ($3.146) | |
| Month Ago EPS | ($0.905) | ($3.584) | ($3.064) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($0.656) | ($3.603) | ($2.895) | |
| Year/Year Chg | 27.8% | (36.9%) | (87.7%) | |
| Financials | ABVX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $6 | $37 | 6% |
|
| Net Income (TTM) (Mil) | ($383) | ($43) | 4% |
|
| EPS (TTM) | ($5.217) | ($1.500) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($206) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $430 | $2 | 90% |
|
| Long-Term Debt (Q1) (Mil) | $38 | $4 | 37% |
|
| Enterprise Value (Q1) (Mil) | $10,068 | $190 | 74% |
|
| Valuation | ABVX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 17.77 | 2.84 | 95% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ABVX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 66.9% | 96% |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (94.4%) | (47.7%) | 6% |
|
| ROE | (156.9%) | (55.0%) | 6% |
|
| Liabilities to Assets | 21.5% | 29.6% | 14% |
|
| F-Score | 3 | 3 | 18% |
|
ABIVAX Société Anonyme did not pass any screens on 9/2/2026.
